SG11202004246YA - Modified ligand-gated ion channels and methods of use - Google Patents

Modified ligand-gated ion channels and methods of use

Info

Publication number
SG11202004246YA
SG11202004246YA SG11202004246YA SG11202004246YA SG11202004246YA SG 11202004246Y A SG11202004246Y A SG 11202004246YA SG 11202004246Y A SG11202004246Y A SG 11202004246YA SG 11202004246Y A SG11202004246Y A SG 11202004246YA SG 11202004246Y A SG11202004246Y A SG 11202004246YA
Authority
SG
Singapore
Prior art keywords
methods
ion channels
gated ion
modified ligand
ligand
Prior art date
Application number
SG11202004246YA
Other languages
English (en)
Inventor
Scott Sternson
Christopher Magnus
Peter Lee
Original Assignee
Hughes Howard Med Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hughes Howard Med Inst filed Critical Hughes Howard Med Inst
Publication of SG11202004246YA publication Critical patent/SG11202004246YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Manufacturing & Machinery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11202004246YA 2017-11-10 2018-11-09 Modified ligand-gated ion channels and methods of use SG11202004246YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762584428P 2017-11-10 2017-11-10
US201862729716P 2018-09-11 2018-09-11
PCT/US2018/060109 WO2019094778A1 (en) 2017-11-10 2018-11-09 Modified ligand-gated ion channels and methods of use

Publications (1)

Publication Number Publication Date
SG11202004246YA true SG11202004246YA (en) 2020-06-29

Family

ID=66438669

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004246YA SG11202004246YA (en) 2017-11-10 2018-11-09 Modified ligand-gated ion channels and methods of use

Country Status (11)

Country Link
US (2) US10961296B2 (de)
EP (1) EP3706743A4 (de)
JP (2) JP2021502101A (de)
KR (1) KR20200087198A (de)
CN (1) CN111556751B (de)
AU (1) AU2018364738A1 (de)
CA (1) CA3082389A1 (de)
IL (1) IL274547A (de)
SG (1) SG11202004246YA (de)
WO (1) WO2019094778A1 (de)
ZA (1) ZA202103620B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019000175A (es) 2016-07-07 2020-01-20 Hughes Howard Med Inst Canales iónicos activados por ligando modificados y métodos de uso.
CA3151920A1 (en) * 2019-08-21 2021-02-25 Coda Biotherapeutics, Inc. Compositions and methods for neurological diseases
WO2023278295A1 (en) 2021-06-29 2023-01-05 The Broad Institute, Inc. Compositions and methods for ameliorating anterodorsal thalamus hyperexcitability
WO2023196851A1 (en) * 2022-04-06 2023-10-12 President And Fellows Of Harvard College Reversing aging of the central nervous system

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL157881A0 (en) * 2001-04-20 2004-03-28 Pfizer Prod Inc Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
GB0229586D0 (en) * 2002-12-19 2003-01-22 Univ London Pharmacy Novel tool for testing pharmacological actives
CA2549638A1 (en) * 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
ATE487716T1 (de) 2004-04-22 2010-11-15 Memory Pharm Corp Indole, 1h-indazole, 1,2-benzisoxazole, 1,2- benzoisothiazole, deren herstellung und verwendungen
WO2007099069A1 (en) * 2006-03-01 2007-09-07 Galderma Research & Development Method of treating inflammatory skin diseases using tropisetron, and pharmaceutical compositions thereof
US8759504B2 (en) * 2007-06-27 2014-06-24 Abbvie Inc. Cholinergic/serotoninergic receptor and uses thereof
US9134307B2 (en) * 2007-07-11 2015-09-15 X-Body, Inc. Method for determining ion channel modulating properties of a test reagent
CL2008003507A1 (es) * 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
WO2010042799A2 (en) 2008-10-09 2010-04-15 Howard Hughes Medical Institute Novel chimeric ligand-gated ion channels and methods of use thereof
TW201109031A (en) 2009-07-31 2011-03-16 Nabi Biopharmaceuticals Method and kit for treating nicotine addiction
WO2011140279A1 (en) * 2010-05-04 2011-11-10 Wayne State University Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
EP3122761B1 (de) * 2014-03-28 2019-03-06 The Board of Trustees of The Leland Stanford Junior University Manipulierte lichtaktivierte anionenkanalproteine und verfahren zur verwendung davon
CN107206106A (zh) * 2014-12-04 2017-09-26 斯坦福大学托管董事会 2型多巴胺受体特异性启动子和其使用方法
CA2998491A1 (en) * 2015-09-17 2017-03-23 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders
MX2019000175A (es) * 2016-07-07 2020-01-20 Hughes Howard Med Inst Canales iónicos activados por ligando modificados y métodos de uso.

Also Published As

Publication number Publication date
WO2019094778A1 (en) 2019-05-16
IL274547A (en) 2020-06-30
KR20200087198A (ko) 2020-07-20
ZA202103620B (en) 2022-10-26
CN111556751A (zh) 2020-08-18
JP2023130435A (ja) 2023-09-20
EP3706743A1 (de) 2020-09-16
CN111556751B (zh) 2024-07-12
US20210206831A1 (en) 2021-07-08
US10961296B2 (en) 2021-03-30
CA3082389A1 (en) 2019-05-16
EP3706743A4 (de) 2022-05-11
AU2018364738A1 (en) 2020-05-28
JP2021502101A (ja) 2021-01-28
US20190169264A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
IL292094A (en) Neoantigens and methods for using them
ZA202101867B (en) Modified ligand-gated ion channels and methods of use
HRP20210526T8 (hr) Oksisteroli i postupci za njihovu uporabu
IL248339A0 (en) Ion channel activators and methods of use
IL282048A (en) Oxysterols and methods of using them
PT3548033T (pt) Compostos e respectivos métodos de utilização
HK1255500A1 (zh) 氧固醇及其使用方法
HK1253049A1 (zh) 糖基相互作用化合物及其使用方法
ZA201905677B (en) Glycan-interacting compounds and methods of use
ZA202103620B (en) Modified ligand-gated ion channels and methods of use
IL267671A (en) Pyrazolopyrimidine compounds and methods of their use
ZA201804228B (en) Cftr regulators and methods of use thereof
ZA201804230B (en) Cftr regulators and methods of use thereof
ZA201804229B (en) Cftr regulators and methods of use thereof
GB201719769D0 (en) Analytical device and methods of use
IL242133B (en) Back-carryable shooting kit and method of use thereof
GB201504575D0 (en) Clamping apparatus and methid of use thereof